| abstract |
The present invention relates to a novel physiological substrate of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), a new effector of QC, a screening method for such an effector, and modulation of QC activity. There is provided such an effector and a pharmaceutical composition comprising such an effector for the treatment of a condition treatable by. Furthermore, preferred compositions are used for the treatment or alleviation of pathologies treatable by modulation of QC and DP IV activity. Contains inhibitors of IV or DP IV-like enzymes. [Selection figure] None |